Older adults who are worried about their thinking, memory, or reasoning skills may want to get tested for Alzheimer’s disease ...

Researchers suggest that the way Alzheimer's reshapes our brains is as unique as our fingerprints, challenging long-held ...

There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to ...

The CE marking clears the way for the company to market its PET system across the EU after launching in the US market in July ...

GE HealthCare has secured the FDA’s approval for an injectable, radioactive imaging agent that gives clinicians a clearer ...

The tests will measure blood-based tau markers, offering a possible alternative to PET imaging for aiding in diagnosis and staging of Alzheimer's disease.

New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported in July. But ...

Alzheimer's disease is a brain disorder affecting millions globally and is becoming more common as populations age.

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease ...

Hot Spot. GWAS of tau PET scans found a single locus where SNPs (circles) were associated with higher tangle loads. The strongest signal came from SNP rs2113389 (gray diamond). [Courtesy of Nho et al.

NEW YORK – The Alzheimer's Drug Discovery Foundation on Wednesday announced that it has invested $7.0 million in Alzheimer's disease diagnostic company C2N Diagnostics. Already have a 360Dx or ...